Domènech E, Garcia-Planella E, Bernal I, Rosinach M, Cabré E, Fluvià L, Boix J, Gassull M A
Department of Gastroenterology, Hospital Universitari Germans Trias i Pujol, Badalona, Catalonia, Spain.
Aliment Pharmacol Ther. 2002 Dec;16(12):2061-5. doi: 10.1046/j.1365-2036.2002.01385.x.
Intravenous ciclosporin is considered to be the only alternative to avoid surgery in severe, steroid-refractory ulcerative colitis. In responders, some authors recommend a switch to oral ciclosporin to act as a 'bridge' until the therapeutic action of azathioprine is achieved for maintenance treatment.
To report the short- and long-term outcome of intravenous ciclosporin-responsive ulcerative colitis patients treated with oral azathioprine without oral ciclosporin.
The records of all patients treated with intravenous ciclosporin for severe, steroid-refractory ulcerative colitis were reviewed. Responders following treatment with azathioprine but without oral ciclosporin as maintenance therapy were included. Patients with colonic cytomegalovirus infection and/or follow-up of less than 1 year were excluded.
Twenty-seven patients were included. Steroids were discontinued in 24 (89%). The median follow-up was 36 months. Eighteen (75%) patients presented mild or moderate relapses, which were easily managed with salicylates or steroids. Cumulative probabilities of relapse were 42%, 72% and 77% at 1, 3 and 5 years, respectively. Eleven (40.7%) patients underwent elective colectomy. Cumulative probabilities of colectomy were 29%, 35% and 42% at 1, 3 and 5 years, respectively. No opportunistic infections were observed.
Oral azathioprine seems to be enough to maintain long-term remission induced by intravenous ciclosporin in patients with steroid-refractory ulcerative colitis. The 'bridging step' with oral ciclosporin may not be necessary in this subset of patients, although a randomized controlled trial is warranted to confirm this hypothesis.
静脉注射环孢素被认为是重度、激素难治性溃疡性结肠炎避免手术的唯一替代方法。对于有反应者,一些作者建议换用口服环孢素作为“桥梁”,直至硫唑嘌呤发挥维持治疗的作用。
报告未使用口服环孢素、接受口服硫唑嘌呤治疗的静脉注射环孢素反应性溃疡性结肠炎患者的短期和长期结局。
回顾了所有接受静脉注射环孢素治疗重度、激素难治性溃疡性结肠炎患者的记录。纳入接受硫唑嘌呤治疗但未使用口服环孢素作为维持治疗的有反应者。排除患有结肠巨细胞病毒感染和/或随访时间少于1年的患者。
纳入27例患者。24例(89%)停用了激素。中位随访时间为36个月。18例(75%)患者出现轻度或中度复发,使用水杨酸盐或激素很容易控制。1年、3年和5年的累积复发概率分别为42%、72%和77%。11例(40.7%)患者接受了择期结肠切除术。1年、3年和5年的累积结肠切除概率分别为29%、35%和42%。未观察到机会性感染。
对于激素难治性溃疡性结肠炎患者,口服硫唑嘌呤似乎足以维持静脉注射环孢素诱导的长期缓解。在这部分患者中,口服环孢素的“过渡步骤”可能并非必要,尽管需要进行一项随机对照试验来证实这一假设。